HRC-302

N/A

Report date: 2025/05/14 18:14:07

Base Information

Drug NameHRC-302
Drug Alias NameAutologous gamma-delta T cell infusion therapy (Hemosol Corp)Gamma-delta T cell therapy (Hemosol Corp)HRC-302HML-115
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHemosol Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHemosol Corp
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A